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The mechanisms by which hyperbaric oxygen and carbogen improve
tumour oxygenation
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S_mman Hyperbaric oxygen (HBO) has been proposed to reduce tumour hypoxia by increasing the amount
of dissolved oxygen in the plasma. That this actually occurs has not been verified experimentally. This study
was performed to explore changes in tumour oxygenation induced by treatment with normobaric and
hyperbanrc oxygen and carbogen. R323OAc mammary adenocarcinomas were implanted into Fischer 344 rats.
Arterial blood gases. blood pressure and heart rate were monitored. Tumour oxygenation was measured
polarographically in five sets of animals. They received either normobaric 100% oxygen, hyperbaric (3
atmospheres, atm) 100% oxygen. normobaric carbogen or hyperbanrc (3 atm) carbogen (HBC) ± bretylium.
HBO reduced the mean level of low pO, values (< 5 mmHg) from 0.49 to 0.07 (P = 0.0003) and increased the
average median pO2 from 8 mmHg to 55 mmHg (P = 0.001). HBC reduced the level of low pO values from
0.82 to 0.51 (P = 0.002) and increased median pO from 2 mmHg to 6 mmHg (P = 0.05). Normobaric oxygen
and carbogen did not change tumour oxygenation significantly. Sympathetic blockade with bretylium before
HBC exposure improved oxygenation significantly more than HBC alone (low pO2 0.55-0.17, median pO2
4-17 mmHg). HBO and hyperbaric carbogen improved tumour oxygenation in this model, while normobaric
oxygen or carbogen had no effect. Syvmpathetic-mediated vasoconstriction dunrng hyperbaric carbogen caused
it to be less effective than HBO. This mechanism also appeared to operate during normobanrc carbogen
breathing.
Keywords: oxygen. hyperbandc oxvgen:
roelectrode
carbogen: tumour oxvygenation: carbon dioxide: polarographic mic-
Thomlinson and Gray (1955) provided indirect evidence that
hypoxic. radioresistant cells existed in human tumours in the
1950s. Their work led to the development of the concept of
chronic, diffusion-limited hypoxia. Some of the earliest
clinical efforts that were designed to overcome chronic
hypoxia utilised hyperbaric oxygen (HBO). The rationale for
these trials was that higher concentrations of dissolved
oxygen in the plasma would provide more gas at the capillary
level and allow diffusion to occur farther into otherwise
hypoxic tissue regions.
Clinical trials of HBO were initiated in the 1950s and
1960s (Brady et al.. 1981; Henk, 1986; Dische. 1991). During
this penrod, several investigators measured tumour oxygena-
tion with simple polarographic microelectrode systems. They
showed that HBO improved tumour oxygenation in animals
and humans (Jamieson and van den Brenk, 1963, 1965).
The effects of carbogen (95% oxygen 5% carbon dioxide)
breathing were also studied. There were two reasons for
using carbogen: the carbon dioxide component would help to
maintain tumour blood flow by counteracting oxygen-
induced vasoconstriction and also increase oxygen delivery
by shifting the haemoglobin-oxygen dissociation curve to
the right (Rojas. 1991). Some studies showed that carbogen
breathing improved tumour oxygenation and blood flow
while others did not (Kruuv et al.. 1967; Inch et al., 1970).
These studies were primarily descriptive in nature and did
not explore potential mechanisms that might explain the
experimental data.
A major limitation of the early polarographic measurement
studies was the inability to sample more than a few points in
any given tumour. The development of a computer-
controlled polarographic device (pO2 histograph. Eppendorf.
Hamburg, Germany) has led to a resurgence in the measure-
ment of tumour oxygenation. Rapid in situ measurement of
multiple points within a tumour is now possible.
Correspondence: DM Bnrzel. Department of Radiation Oncology.
Box 3085. Duke University Medical Center. Durham. NC 27710. USA
Received 20 December 1994: revised 26 June 1995: accepted 7 July
1995
Recently, some investigators have reintroduced carbogen
into the clinic to attempt to improve tumour oxygenation.
Falk et al. (1992) have demonstrated that carbogen tran-
siently improves tumour pO, in humans. Whether or not this
improvement is greater than that which would result from
pure oxygen is not known.
The study reported here was performed in an animal
tumour model to measure changes in tumour oxygenation
induced by treatment with oxygen and carbogen under nor-
mobaric and hyperbaric conditions. Based on the existing
data, our hypothesis was that HBC would increase tissue
oxygenation to a greater extent than the other modalities.
The study was also designed to evaluate possible physio-
logical mechanisms that could explain any observed
differences.
Materials and methods
Aninal model
Female Fischer 344 rats weighing 150-170 g had mammary
adenocarcinomas (R3230Ac) implanted subcutaneously into
the left flank. Tumour size varied from 10-25 mm in
diameter. Animals were anaesthetised with intraperitoneal
injections of Nembutal (pentobarbital sodium) at a dose of
40 mg kg-' body weight. Tracheostomy was performed to
allow mechanical ventilation at a rate of 50-60 breaths per
min. An arterial line was placed into the right femoral artery
to monitor blood pressure. The animals were placed on a
warming pad to maintain body temperature close to 37°C.
Tumour oxygen measurement
Tumour oxygenation was measured with the Eppendorfp02
histograph. A two-point calibration of the electrode was
performed immediately before and after each series of
measurements using buffered 0.9% sodium chloride, pH 7.8,
which was equilibrated alternately with room air (21%
oxygen) and pure nitrogen under normobaric conditions or
7% oxygen and pure nitrogen under hyperbaric conditions at
3 atm.After the initial calibration, a silver-silver chloride
reference electrode was inserted into the right flank of the
animal and polarised to a voltage of -700mV. A small
incision was made in the skin over the tumour, and the
electrode was inserted approximately 1 mm into the tumour.
The electrode was allowed to stabilise. It was then advanced
into the tumour in a stepwise fashion consisting of 0.7 mm
forward and then 0.3 mm backward. Serial measurements
were thus obtained with a net distance of 0.4 mm between
points. Measurements were taken along 4-6 tracks at
various locations within each tumour until 100 data points
were obtained. The electrode was then recalibrated. Arterial
blood gas values, heart rate and blood pressure were
recorded continuously during each measurement series both
under control and experimental conditions. The average
values were computed for each parameter.
Experimentalprotocol
Five sets of experimental manipulations were performed in
this study. They consisted of normobaric 100% oxygen,
hyperbaric (3 atm) 100% oxygen, normobaric carbogen and
hyperbaric (3 atm) carbogen. After preliminary analysis of
these experiments a fifth set of animals received an int-
ravenous injection of bretylium followed by exposure to
hyperbaric carbogen.
Each animal underwent control tumour p02 measurements
while breathing normobaric room air. The mechanical ven-
tilator was adjusted so that the blood gas values would fall
into a 'normal' range (pH approximately 7.45-7.55; pO2
>60mmHg; and pCO2 approximately 30mmHg). Each
animal therefore served as its own control and no animal
received more than one type of experimental treatment.
Treatment with normobaric oxygen or carbogen
Following the control measurements, the ventilator was set
to provide 100% oxygen or carbogen for the animal while
the breathing rate was not altered. A series of 100
measurements was obtained after the animal had breathed
oxygen or carbogen for 5 min. A second set ofmeasurements
was obtained after 25 min in the animals that were breathing
carbogen.
Treatment with hyperbaric oxygen
The entire apparatus, including the ventilator, the animal and
the p02 histograph, were set up inside a large hyperbaric
chamber. The chamber was large enough for the investigators
(DB, SL, JB) to accompany the animals during the
experiments. Control measurements were performed under
normobaric conditions. The chamber was then presurised to
3 atm (approximately 2280mmHg). Ambient concentration
ofoxygen in the chamber was 7% while the animals breathed
100% oxygen from the ventilator. The electrode was recalib-
rated with 7% oxygen (21% surface equivalent) and pure
nitrogen. A series of 100 measurements was made after the
animal had breathed pure oxygen under hyperbaric condi-
tions for 5 min. The probe was recalibrated afterwards, and
then the chamber was decompressed to 1 atm.
Treatment with hyperbaric carbogen
The procedure was similar to that for the hyperbaric oxygen
expenment, but two sets of measurements were made, at
5 min and 25 min after the animal started carbogen
breathing.
Treatment with bretyliwn andhyperbaric carbogen
Animals received an i.v. infusion of bretylium tosylate
(Bretylol, Du Pont Pharmaceuticals, Wilmington, DE, USA;
0.4ml of a 17mgml-' solution) over a 20min period to
provide a blockade of the sympathetic nervous system. The
hyperbaric chamber was pressurised, and the probe was
DM Brze eti
1121
calibrated. Measurements were performed 20-25min after
completion of the bretylium infusion and approximately
S min after initiation of carbogen breathing. A second series
of measurements was not performed in this group ofanimals
as the required extra time at pressure would have necessitated
a prolonged decompression period for the investigators.
Statistical considerations
Paired t-tests were used to compare control and experimental
measurements within the same group. Repeated measures
analysis of vanance was used to determine if there were
sipificant differences between the different experimental
groups. To adjust for differences in tumour volume between
experimental groups, models were fit including tumour
volume as a covariate. These models indicated that adjust-
ment was not necessary and tumour volume was not included
in the final models. Models were also fit using mean arterial
blood pressure, heart rate and arterialpO2 as tim-dependent
covariates. Adjusting for these variables also had little effect
on the results.
Results
A frequency histogram that illustrates overall patterns of
oxygenation for the HBO, HBC and bretylium/HBC groups is shown in Figure 1. Table I summarises the changes in
tumour oxygenation that resulted from the different thera-
peutic manipulations. No significant changes in the percen-
tage of low pO2 values (<5mmHg) or median pO2 resulted
from treatment with NBO or NBC. Highly significant improvement in both of these parameters occurred after
S min of HBO breathing. The mean low pO2 fraction (LF) decreased from 0.49 to 0.07 while the average median p02 incrased from 8mmHg to 55mmHg (P= 0.0003 and 0.001
respectively). HBC reduced LF from 0.82 to 0.59 at 5 min.
An additional 20min of HBC breathing led to a further decrease to 0.51 (P= 0.003 and 0.002 respectively). Median
P02 was unchanged at 5 min but increased to 6mmHg at
25 min (P =0.05).
The baseline LFs of the HBO animals were significantly lower than those of the HBC group (P<0.001). Therefore, the changes in LF at 5 min were compared between the two
sets ofanimals. The change of0.42 for HBO vs 0.23 for HBC
was of borderline signnce (P=0.07). Adjustments for
differences in tumour volume, mean arterial pressure, heart
rate and arterial pO2 (Table II) did not affect this com-
parison. Nonetheless, the fact that HBC did not improve
tumour oxygenation more than HBO was somewhat unex- pected.
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Fuwe I Frequency histograms illustrating the overall distribu- tions of tumour pO2 for the groups of animals receiving hyper- baric oxygen, hyperbaric carbogen (after 5 mm of breathing) and
bretyllum followed by hyperbaic carbogen. The two shaded cohluns at the left indicate the fraction oflowpO2 measurements (< 5 mmHg) for each group.-yeb'u 0Zq and -ua
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Table I Summary ofchanges in tumour oxygenation
Median
Treatment n Low pO P-value p0 P-value
Room air 11 0.49 8
HBO 0.07 0.0003 55 0.001
Room air 8 0.53 4
NBO 0.68 0.17 3 0.46
Room air 8 0.71 1
NBC (5min) 0.53 0.12 4 0.20
NBC (25 min) 0.62 0.30 2 0.64
Room air 8 0.82 2
HBC (5min) 0.59 0.003 2 0.15
HBC (25 mn) 0.51 0.002 6 0.05
Room air 4 0.55 4
Bretylium + HBC 0.17 0.01 17 0.09
HBO, hyperbaric 100% oxygen; NBO, normobaric 100% oxygen;
NBC, normobaric carbogen; HBC, hyperbaric carbogen. Low p02.,
proportion ofmeasured pointswithpO2 <5 mmHgaveraged across all
animals in individual experimental groups. Median P02, the median
value of individual median pO, values in each group.
The fact that HBC did not improve tumour oxygenation
more than HBO led us to consider that the carbon dioxide
may have been eliciting a sympathetic reflex vasoconstriction.
Consequently, two additional sets of experiments were per-
formed in which animals received bretylium to assess the
effect of sympathetic blockade before carbogen exposure. In
these experiments, median P02 increased from 4mmHg to
17mmHg (P= 0.09), and LF decreased from 0.55 to 0.17
(P = 0.02). The improvements in these oxygenation para-
meters with the addition of bretylium compared with those
which were seen with HBC alone were highly significant
(P = 0.01 and P<0.00I respectively). The improvements in
tumour oxygenation from bretylium/HBC were not sig-
nificantly different from those seen with HBO (P = 0.16). The
augmentation in oxygenation that resulted from pretreatment
with bretyhum was particularly striking in the context of the
reduction in mean arterial pressure (MAP) that this drug
caused. MAP fell from 112 mmHg to 65mmHg (P=0.001).
Figure 2a compares the relative changes in LF for the
HBO-, HBC- and bretylium/HBC-treated tumours. The
baseline LFs were normalised to 1, since this parameter
varied among the different groups, in order to more easily
compare the changes in oxygenation. Similarly, Figure 2b
shows the relative change in median P02 after 5 min of
exposure to HBO, HBC and bretylium/HBC.
Tumour tissue oxygenation is the net outcome of a complex
series of processes that influence oxygen supply and demand.
Hypoxia results when the supply is inadequate to meet
demand. Many efforts have been directed towards overcom-
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Fgue 2 (a) Relative changes in the proportion of low p02
values (<5 mmHg) for the animals receiving hyperbaric oxygen
( ), hyperbaric carbogen ( after min of breathing) and
bretylium followed by hyperbaric carbogen ( ). The baseline
for each group has been normalised to I ( [=) to allow a better
comparison among the different groups. (b) Relative changes in
the median tumour p02 for the animals receiving hyperbaric
oxygen ( X ), hyperbaric carbogen ( M after 5 min of
breathing) and bretylium followed by hyperbaric carbogen
( _ ). The baseline for each group has been normalised to I to
allow a better companrson among the different groups.
ing tumour hypoxia because of the relative radioresistance of
hypoxic cells. Two approaches have commonly been em-
ployed focusing on augmentation of tumour oxygenation or
selective targeting of hypoxic regions. Examples of the
former include the use of perfluorocarbons, blood trans-
fusions, oxygen and/or carbogen breathing during treatment,
and HBO (Brady et al., 1981; Henk, 1986; Lustig et al., 1989,
1990; Dische, 1991; Rockwell et al., 1991). The latter would
include the use of nitroimidazoles and bioreductive agents
Tabie n Tumour size and physiological parameters
Treatment n Diameter MAP HR paO2 paCO.
Room air 11 17 ± 3.7 128 460 74 28
HBO 129 460 1455 29
Room air 8 15 ± 3.6 136 463 70 23
NBO 146 505 395 20
Room air 8 18 ± 2.5 134 454 79 23
NBC 133 467 503 43
Room air 8 17 ± 2.6 136 460 76 23
HBC 128 460 1372 91
Room air 4 14 ± 1.7 112 450 73 28
Bretylium,HBC 65 455 1365 95
All data represent median values except diameter which is mean ± s.d. MAP.
mean arterial pressure: HR, heart rate; paO,, arterial pO2; paCO.. arterial pCO2.
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such as misonidazole, mitomycin C or SR-4233 (Rockwell,
1992).
Secomb et at. (1995) recently analysed the effects of oxygen
supply and demand on tumour hypoxic fraction, which they
defined as the proportion of p02 measurements <3 mmHg.
The model used by these investigators incorporated blood
flow rate, blood oxygen content and oxygen consumption
rate into the calculation of the hypoxic fraction of a given
tumour region. The vascular geometry that they used was
taken from morphological observations of the R3230AC
tumour, the same type used in the current studies. The other
parameters also were based on experimentally derived data.
The hypoxic fraction could be eliminated by reduction of the
oxygen consumption rate by 30%. On the supply side, how-
ever, flow rate had to be increased 4-fold and arterial p02
(paO2) by a factor of 11 in order to eliminate tumour
hypoxia.
Normobaric oxygen and carbogen caused no signifit
change in tumour oxygenation in the current study while
HBO and HBC led to improvement. Both NBO and NBC
increased paO2 by a factor of 5-6 (395 mmHg for NBO and
503 mmHg for NBC). HBO and HBC increased it by a
factor of approximately 20. If we redefined LF in the
current study by Secomb et al.'s (1995) 3 mmHg criterion,
then breathing normobaric oxygen, normobaric carbogen
(mesured at 5 min), HBO and bretylium/HBC resulted in
fractions of 0.42, 0.44, 0.09 and 0.03 respectively. These
changes inpaO2 and the corresponding reductions in LF are
consistent with what is predict by the Secomb model.
Ongoing clinical trials are utilising carbogen to attempt to
improve tumour oxygenation. The rationale for the use of
the 95% oxygen component is to deliver more oxygen to the
tumour. The carbon dioxide is supposed to maintain tumour
blood flow via peripheral vasodilation and shiffing of the
haemoglobin-oxygen dissociation curve to the right, which
favours oxygen unloading in the tumour (Rojas, 1991). Mar-
tin et al. (1993) analysed the effect of crbogen breathing on
tumour oxygenation with the pO2 histograph in head and
neck cancer patients with metastases to cervical lymph nodes.
Median P02 improved in most tumours. However, the back-
ward movement of the probe (0.1 mm) and the net forward
probe movement (0.2mm) were kss than that used in the
current study (0.3 mm and 0.4 mm respectively) and are leks
than that recommended by the manufacturer (M Gunderoth,
personal communication). The shorter net distance between
measured points inctreases the chance that haemorrhage from
a previous measurement could contaminate subsequent
measurements. In such a situation, the higherpaO2 from any
inspired gas could erroneously lead one to conclude that
tissue P02 was increased.
Siemann et al. (1977) showed in an animal model that a
priradiationcarbogen breathing time (PEBT) of 10minpro-
duced a maxum radiosensitisation. As PIBTs increased up
to 90 min, radiosensitivity returned to the basei leveel seen
with air breathing. Similarly, Inch et al. (1970) showed that a
0.5 min cabogen PIBT more effectively radiosensitised than
a 12 minPIBT. Falk et al. (1992) recently observed the same
general sequence of changes in a clinical trial where human
patients underwent serial sets of pm2 msurements with the
p02 histograph while breathing carbogen. Median tumour
p2 increased in 12 out of 17 patients after 8-12min of
carbogen breathing. With additional carbogen exposure,
tumour oxygenation returned towards baseie in many of
these patients. Similarly, in the current study, LF decreased
and Median p02 increased, albeit in a statistically non-
signifant fashion, during the first 5 mm of normobaric
carbogen exposure and then returned towards the baseline
control values with additional carbogen breathing. These
time-dependent findings aresimilar to those of the previously
investigators (Jamieson and van den Brenk, 1965; Inch
al., 1970;Siemann, 1977; Falk et al., 1992). They differ
from majority
of other investigators' findings of carbogen-
mediated increases intumour oxygenation and/or radiosen-
sitisation (Kruuv et al., 1967; Rockwellet al., 1991; Rojas,
1991; Grau et al., 1992; Chaplin et al., 1993; Martin et al.,
1993; Horsman et al., 1994; Siemann et al., 1994). Hyper-
baric carbogen did improve tumour oxygenation signifi-
cantly, but, contrary to our expectations, the magnitude of
improvement did not exceed that caused by HBO.
The effects of normobaric and hyperbaric carbogen on
tumour oxygenation that we observed do not fit into Secomb
et al.'s (1995) model even though the latter increased paO2
from 76mmhg to 1372mmHg. The effect of these two gases
can be interpreted, however, by consideration of the direct
and indirect effects of carbon dioxide exposure on the vas-
culature. NBC and HBC caused paC02 to increase to
43mmHg and 91 mmHg respectively. Carbon dioxide inhala-
tion provides a very potent stimulus in the brainstem that
results in activation of the sympathetic nervous system
(Richardson et al., 1961). Blood flow to the forearms
decreases in patients breathing high concentrations ofcarbon
dioxide (Blair et al., 1961). Blood flow increases, however, if
a nerve block is performed beforehand (Hampson et al.,
1987). Conversely, carbon dioxide causes vasodilation and
decreased total peripheral resistanc (TPR) in sympathec-
tomised limbs but vasoconstriction and increased TPR in
non-sympathectomised limbs (Steck and Gellhorn, 1939).
Thus, the direct effect of carbon dioxide breathing is
peripheral vasodilation and increased blood flow, but this is
masked by indirect, sympathetic effects that override the
direct effects ofcarbon dioxide and result in vasoconstriction
and a net decrease in flow.
That HBC was not more effective than HBO in improving
tumour oxygenation would appear to be the result of
adrenergic stimulation from the inspired carbon dioxide.
HBC breathing preceded by the injection ofbretylium, which
is a potent sympatholytic agent, was signintly superior to
HBC alone. This fact provides strong, direct evidence to
support the argument that central sympathetic control
mechanisms interfere with the direct dilator effects of carbon
dioxide. The pronounced decrease in MAP caused by
bretylium indicates that the dose of this agent that we used
provided a complete sympathetic blockade. The improvement
in tumour oxygenation with bretylium/HBC is even more
striking in view of the extent of this decrease in MAP.
The direct vasodilatory effects and the idirect sympathetic
vasoconstrictor effects of carbon dioxide also offer a possible
explanation for the normobaric carbogen-induced changes
observed both in preclinical studies, including ours, and in
human investigations (Jamieson and van den Brenk, 1963,
1965; Kruuv et al., 1967; Inch et al., 1970; Siea nn et al.,
1977; Falk et al., 1992). An initial improvement in tumour
oxygenation followed by a return towards baseline could
occur if the direct effects predominated initially and were
superceded by the indirect effects with additional carbogen
breathing.
Many investigators have studied tumour oxygenation in
awake patients or animals while the animals in the current
study were anaesthetised. The anaesthea could have
adverselyaffected blood flow and oxygen delivery. This is not
hikely, however, as the baseline haemodynamic parameters
(MAP, HR,arterial pO,J for these animals were not different
from what has been reported when they are awake (Smith et
al., 1985). Nembutal can also depress respiratory drive which
could adverselyaffect tissue oxygenation. We also thinkl that
this is unlkely to have been a problem because the animals
in this sudy were mechaniclly ventilated at rates at which
they breathe when conscious. Furtermore, the experimental
gases caused no major changes in any of the haemodynamic
parameters except in the case of bretylium/HBC where the
intent was sympathetic blockade and where a decrease in
MAP was enct. We believe that performing oxygen
measurements on anaesthetised animals is as valid as doing
them on restrained, awake animals where stress and discom-
fort could cause catecholamine-induced changes in blood
flow and oxygenation.
Baselinetumour oxygenation was best in the HBO animals
and became progressively worse as different animals were
exposed to NBO, NBC and HBC. The greater reduction in
LF inthe HBO animals compared with the HBC animals
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was of borderline significance. It is possible, however. that
improving tumour oxygenation is more difficult in very
hypoxic tumours.
The tumours in the NBO. NBC and HBC groups may also
have been more necrotic than the HBO tumours even though
there were no differences in tumour diameter. Polarographic
electrodes cannot distinguish between hypoxic, viable tissue
and necrotic tissue. Under conditions of necrosis, no
therapeutic manipulation would be expected to improve
oxygenation.
The number of measurement tracks performed does repre-
sent a potentially confounding variable in the interpretation
of the data. Since 4-6 tracks were obtained per procedure
and since each animal served as its own control, from 8-18
tracks (2-3 determinations x 4-6 tracks) could have been
made in any given tumour. Oedema and haemorrhage from
the trauma could have led to an overestimation or underes-
timation of tumour oxygenation. It is likely, however, that
this type of problem would have affected all of the different
experimental groups equally.
Conclusion
The present study demonstrated that hyperbaric oxygen and
hyperbaric carbogen improved tumour oxygenation in the
R3230AC mammary carcinoma implanted in the hindlimb.
Sympathetic-mediated vasoconstriction during carbogen
breathing prevented the latter from being more effective than
HBO. This mechanism also appeared to operate during nor-
mobaric carbogen breathing. It may also explain the findings
obtained in the human studies of carbogen breathing. We
will evaluate the extent to which these manipulations of
tumour oxygenation influence the response to ionising
irradiation in future animal studies.
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